Newswise — Dana-Farber Cancer Institute (Boston, MA, USA) and Gustave Roussy (Villejuif, France) have announced the Second Transatlantic Exchanges program will focus on artificial intelligence (AI) and data science in oncology.

Global leaders from the organizations will present the latest findings and trends in AI and its impact on clinical oncology in Paris at on May 5, 2023, during a day-long session.

The meeting, supported by l’Institut Servier, to be held in-person at Boissière Conference Center, Paris 75116 and livestreamed virtually on Medscape’s platform, will be chaired by Prof. Toni K Choueiri, Medical Director, International Strategic Initiatives and director of the Lank Center for Genitourinary Oncology, Dana-Farber and Prof. Karim Fizazi, head of international academic network at Gustave Roussy and moderated by Prof. Fabrice André, Gustave Roussy’s director of research,. Other presenters include:   Eliezer Van Allen, MD, Chief, Division of Population Sciences, and prof. Franziska Michor, PhD, professor of Computational Biology, Dana-Farber and Prof. Paul Henry Cournède, Director of Research at CentraleSupélec, Université Paris-Saclay.

 “AI has great application and tremendous promise in oncology. Through this collaboration, I look forward to sharing our expertise and learning from colleagues as we explore this area further,” said Toni Choueiri.

“This second edition of the Transatlantic Exchanges around AI will be just as exciting; the level of speakers is impressive. Sharing knowledge and advances on this constantly evolving topic is essential to lead its development and its dissemination for the benefit of patients living with cancer,” said Prof. Fabrice André, director of research, Gustave Roussy.

“One year after a first successful session focused on immuno-oncology in Boston in May 2022, the Transatlantic Exchanges Conference is back, this year in Paris, dedicated to AI and Data Science in Oncology. No doubt that the panel of distinguished speakers from both sides of the Atlantic will deliver top notch lectures in this fast-moving field. From imaging to pathology and innovative therapeutic approaches, AI opens new avenues in the cancer field. We are looking forward to learning the latest news for the patients’ benefit”, said Prof. Gérard Friedlander, chairman of L’Institut Servier Scientific Committee.

This Transatlantic Exchanges Program is part of a two-year Collaboration agreement between Dana-Farber, Gustave Roussy with the support of L’Institut Servier that includes annual conferences, alternating between Boston and Paris, and a fellowship program for four young researchers, post-doctoral students from Gustave Roussy, who are hosted in research labs of Dana-Farber. The 2022 meeting held in Boston focused on Immuno-Oncology.

This meeting is open to healthcare professionals with an interest in oncology via our delegate engagement hub (leveraging Medscape Global Medical Affairs). Virtual registration is now open here.

If you are in Paris and wish to attend the meeting in person, register at



About Dana-Farber Cancer Institute Dana-Farber Cancer Institute is one of the world’s leading centers of cancer research and treatment. Dana-Farber’s mission is to reduce the burden of cancer through scientific inquiry, clinical care, education, community engagement, and advocacy. Dana-Farber is a federally designated Comprehensive Cancer Center and a teaching affiliate of Harvard Medical School.  

We provide the latest treatments in cancer for adults through Dana-Farber Brigham Cancer Center and for children through Dana-Farber/Boston Children’s Cancer and Blood Disorders Center. Dana-Farber is the only hospital nationwide with a top 5 U.S. News & World Report Best Cancer Hospital ranking in both adult and pediatric care. 

As a global leader in oncology, Dana-Farber is dedicated to a unique and equal balance between cancer research and care, translating the results of discovery into new treatments for patients locally and around the world, offering more than 1,100 clinical trials.  



About Gustave Roussy

Ranked as the leading European Cancer Centre and third in the world by Newsweek, Gustave Roussy is a center with comprehensive expertise and is devoted entirely to patients suffering with cancer. The Institute is a founding member of the Paris-Saclay Cancer Cluster. It is a source of diagnostic and therapeutic advances. It caters for almost 50,000 patients per year and its approach is one that integrates research, patient care and teaching. It is specialized in the treatment of rare cancers and complex tumors and it treats all cancers in patients of any age. Its care is personalized and combines the most advanced medical methods with an appreciation of the patient’s human requirements. In addition to the quality of treatment offered, the physical, psychological and social aspects of the patient’s life are respected. 4,100 professionals work on its two campuses: Villejuif and Chevilly-Larue. Gustave Roussy brings together the skills, which are essential for the highest quality research in oncology: 40% of patients treated are included in clinical trials. 

For further information:, Twitter, Facebook, LinkedIn, Instagram



About L’Institut Servier

L’Institut Servier is a non-profit association under French law. It aims to perpetuate the values of the Servier Group through a desire to develop research in all its forms and contribute to medical knowledge for patient well-being.

L’Institut Servier supports research and fosters vocations through its research grants program for

Young researchers and through Prizes, Grants and Donations awarded to research teams, academic institutions and foundations recognized as being of public benefit and whose purpose is to promote medical research.

The activities of L’Institut Servier focus primarily on the following therapeutic areas: oncology, immuno-inflammation, neurodegenerative diseases, and pediatric diseases.

For further information:,Linkedin


About Medscape Medical Affairs

Medscape Medical Affairs partners with Medical Affairs teams to facilitate optimal collaboration between internal teams, physicians, and the broader medical community. By working with medical affairs professionals, Medscape Medical Affairs allows them to take a more strategic leadership role and maximize the impact of medical activities in accelerating the adoption of life-changing therapies into clinical practice.